文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

Nat Biotechnol. 2004 Aug;22(8):953-7. doi: 10.1038/nbt0804-953.

Drug development is a risky business, and the final product can have serious, sometimes deadly flaws. But by focusing on fixing those flaws, companies are catapulting themselves to profitability.

药物研发是一项风险极高的业务，最终产品可能存在严重的、有时甚至是致命的缺陷。但通过专注于修复这些缺陷，企业正在迅速实现盈利。

相似文献

Redesigner drugs.新型毒品

Nat Biotechnol. 2004 Aug;22(8):953-7. doi: 10.1038/nbt0804-953.

Biotech patents-business as usual?生物技术专利——一切照旧？

Nat Biotechnol. 2008 Dec;26(12):1326. doi: 10.1038/nbt1208-1326.

Cost-effectiveness data on biologics needed.需要生物制剂的成本效益数据。

Nat Biotechnol. 2005 Mar;23(3):272-3. doi: 10.1038/nbt0305-272.

Maximizing exclusivity for drug products.最大化药品的独家性。

Nat Rev Drug Discov. 2005 Sep;4(9):709. doi: 10.1038/nrd1829.

Pharmaceutical Portfolio & Product Life Cycle Management--SMi's fourth annual conference. 29-30 June 2009, London, UK.制药产品组合与产品生命周期管理——SMi第四届年度会议。2009年6月29 - 30日，英国伦敦

IDrugs. 2009 Sep;12(9):558-60.

EU to review rare disease drugs market exclusivity.欧盟将审查罕见病药物的市场独占权。

Nat Biotechnol. 2004 Sep;22(9):1061. doi: 10.1038/nbt0904-1061.

The quiet revolution.悄然变革。

Nat Biotechnol. 2003 Jul;21(7):715. doi: 10.1038/nbt0703-715.

Unlocking the money-making potential of RNAi.挖掘RNA干扰的盈利潜力。

Nat Biotechnol. 2003 Dec;21(12):1441-6. doi: 10.1038/nbt1203-1441.

Patent indicators: a window to pharmaceutical market success.专利指标：洞察医药市场成功的窗口。

Expert Opin Ther Pat. 2013 Jul;23(7):765-71. doi: 10.1517/13543776.2013.792806. Epub 2013 Apr 23.

Putting your best mode forward.展现出你最好的状态。

Nat Biotechnol. 2000 Oct;18(10):1113-4. doi: 10.1038/80327.

Nat Biotechnol. 2004 Aug;22(8):953-7. doi: 10.1038/nbt0804-953.

Drug development is a risky business, and the final product can have serious, sometimes deadly flaws. But by focusing on fixing those flaws, companies are catapulting themselves to profitability.

药物研发是一项风险极高的业务，最终产品可能存在严重的、有时甚至是致命的缺陷。但通过专注于修复这些缺陷，企业正在迅速实现盈利。